GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I love the fact that we can find drug X out there that is super expensive and already approved and in use but with patent rights set to expire within a window.<

Patent rights may not come into play to the same degree they do with small molecules because a transgenic knockoff of a drug will likely be different enough from the original to make an end run around a composition-of-matter patent.

Therapeutic “use” patents may come into play, but these tend to be less of an impediment than composition-of-matter patents.